ClinicalTrials.gg
RecruitingNCT07675018INVICTUSUpdated Oct 30, 2026

INterest of the Negative Predictive Value of Integrons in the reduCtion of Large Broad-spectrum anTibiotics Consumption for Urinary Tract infectionS

An interventional study of Detection of integrons and Gold standard in Drug Resistance, Microbial, Biomarkers and Urinary Tract Infections (UTI's), sponsored by University Hospital, Limoges. Recruiting at 7 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by University Hospital, Limoges · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 30, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
204
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 58 studies in Urinary Tract Infections with a site in France — 10 open to participants now, 11 under way, 1 of them phase 3. Urinary Tract Infections · France.

Planned enrollment
11th of 34
204 · median 131
Started
2026
with 3 others
No phase
19 of 58
3 open now
Primary completion
2028-09
later than 8 of 10 live
Registered
58th of 58
by date
Lead sponsor
4 of 58
University Hospital, Limoges

Among the 58 studies in Urinary Tract Infections with a site in France, this one is the 11th largest by planned enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2026, is one of 19 with no phase, reaches primary completion later than 8 of the 10 other live ones, and was the 58th registered.

Urinary Tract Infections

808 studies on the registry are indexed under Urinary Tract Infections; 135 are open to participants now.

Browse Urinary Tract Infections studies →

Open to participants now

10 of the 58 studies in Urinary Tract Infections with a site in France are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 84 Urinary Tract Infections studies recruiting now, 51 (61%) set no upper age limit and 23 (27%) stop at 75 or younger; 17 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Urinary Tract Infections with a site in France, or all of them as a file.
02

Study summary

Urinary tract infections (UTI), mainly driven by Gram-negative bacteria (GNB) are a frequent cause of hospitalization and the second cause of antibiotic prescription after lower respiratory tract infections. Integrons play a major role in the dissemination of antibiotic resistance among GNB. In the prospective INVICTUS project, whose ultimate objective is to reduce the use of large broad-spectrum antibiotics, our hypothesis is that, in adult patients with a non-severe UTI (qSOFA\<2) and a former documentation with a 3GC-resistant GNB in the previous 6 months, integrons search could reduce the empirical use of large broad-spectrum antibiotics.

Read the detailed description

The promotor conducted a multicenter prospective study, IRIS (Interest of integrons as predictive markers of acquired antibiotic Resistance in patients with urinary or Intra-abdominal Sepsis) which showed that integrons have a high negative predictive value (NPV) for antibiotic resistance. Among the 343 patients admitted in the ED or intensive care units (ICU) with a urinary sepsis, the NPV of integrons, by detecting them directly form urine samples, was 96.6% (CI:94.0-98.6%) for resistance to 3GC. Whether the detection of integrons to predict antibiotic resistance could efficiently guide empirical antibiotic therapy of patients with a UTI remains to determine. INVICTUS aims at providing the front-line ED physician with additional valuable information using molecular detection of integrons, to best guide adequate first-line antibiotic therapy, while sparing large broad-spectrum antimicrobial agents. In the experimental arm, empirical parenteral antibiotic therapy will be guided based on the detection of integrons. If integrons detection is positive, a large broad spectrum therapy with ureidopenicillin and β-lactamase inhibitors combinations (Piperacillin-Tazobactam) or carbapenems (Imipenem, Meropenem) will be prescribed. If integrons detection is negative, patient will receive a parenteral 3GC (Ceftriaxone, Cefotaxime, Ceftazidime or Cefepime). In the control arm, the comparative treatment will be an empirical antibiotic therapy with ureidopenicillin and β-lactamase inhibitors combinations (Piperacillin-Tazobactam) or carbapenems (Imipenem, Meropenem) at clinician's discretion. For the primary analysis, the number of days with large broad-spectrum antibiotic therapy during the first week will be compared between the two groups using a Student t-test.

03

Conditions studied

  • Drug Resistance, Microbial
  • Biomarkers
  • Urinary Tract Infections (UTI's)
  • Antibacterial Agents

Keywords

  • Integron
  • Antimicrobial Stewardship
  • Antimicrobial Resistance
  • Urinary Tract Infections
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years old; Hospitalized or admitted to the Emergency department;
  • Diagnosis of non-severe (qSOFA \< 2) urinary tract infection coupled with fever ≥ 38°C or \< 36°C
  • Presence of bacteria in the fresh urine sample and/or GNB on the Gram stain
  • Empirical parenteral antibiotic therapy required; Hospitalization required;
  • Former documentation of a 3GC-resistant GNB on a microbiological sample in the previous six months
  • of the patient or their representative

Exclusion criteria

Exclusion Criteria:

  • Pregnant and/or breastfeeding
  • Neutropenia ( \< 500 / mm3)
  • Severe UTI with sepsis (qSOFA ≥ 2) or septic shock
  • Urinary derivation required (ureteral catheter/per-cutaneous nephrostomy) except for simple urinary catheterization
  • Known allergy to β-lactams
  • Patients with a former documentation with carbapenemase-producing Enterobacterales in the last 6 months
  • Ongoing antibiotic treatment with 3GC, piperacillin-tazobactam or carbapenem
  • Not affiliated to Social Security
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
204 participants (estimated)

Study arms

  • Experimental
    Empirical parenteral antibiotic therapy based on the detection of integrons

    In the experimental arm, empirical parenteral antibiotic therapy will be guided based on the detection of integrons. If integrons detection is positive, a large broad spectrum therapy with ureidopenicillin and β-lactamase inhibitors combinations (Piperacillin-Tazobactam) or carbapenems (Imipenem, Meropenem) will be prescribed. If integrons detection is negative, patient will receive a parenteral 3GC (ceftriaxone, cefotaxime, ceftazidime or cefepime). The treatment will be started after the integron detection

    Diagnostic Test: Detection of integrons

  • Active comparator
    Empirical antibiotic therapy with ureidopenicillin and β-lactamase inhibitors combinations

    In the control arm, the comparative treatment will be an empirical antibiotic therapy with ureidopenicillin and β-lactamase inhibitors combinations (Piperacillin-Tazobactam) or carbapenems (Imipenem, Meropenem) at clinician's discretion. The treatment will be started after the randomization

    Other: Gold standard

Interventions

  • Diagnostic testDetection of integrons

    Empirical parenteral antibiotic therapy will be guided based on the detection of integrons. If integrons detection is positive, a large broad spectrum therapy with ureidopenicillin and β-lactamase inhibitors combinations (Piperacillin-Tazobactam) or carbapenems (Imipenem, Meropenem) will be prescribed. If integrons detection is negative, patient will receive a parenteral 3GC (ceftriaxone, cefotaxime, ceftazidime or cefepime). The treatment will be started after the integron detection.

  • OtherGold standard

    The comparative treatment will be an empirical antibiotic therapy with ureidopenicillin and β-lactamase inhibitors combinations (Piperacillin-Tazobactam) or carbapenems (Imipenem, Meropenem) at clinician's discretion. The treatment will be started after the randomization

06

What researchers measure

Primary outcomes

  1. Number of days with large broad-spectrum antibiotic therapy

    Number of days with large broad-spectrum antibiotic therapy (ureidopenicillin and β-lactamases inhibitor combinations or carbapenems) during the first week of treatment (i.e., until Day 7 after admission) in the experimental arm compared to the number of days with large broad-spectrum antibiotic therapy in the control arm

    Time frame: Day 7

Secondary outcomes

  1. Proportion of patients with clinical resolution of UTI

    Proportion of patients with clinical resolution of UTI, i.e. 2 consecutive temperature assessment \< 38°C and ≥ 36°C (with a minimum interval of 3 hours) within the first 48 hours after the first parenteral antibiotic administration

    Time frame: Day 7

  2. Proportion of patients for whom the empirical antibiotic therapy

    Proportion of patients for whom the empirical antibiotic therapy was adapted to the AST

    Time frame: Day 7

  3. Proportion of patients, for whom the integron detection result was consistent with the AST

    Proportion of patients, in the experimental arm, for whom the integron detection result was consistent with the AST (i.e., true positives + true negatives, AST being the gold standard)

    Time frame: Day 7

  4. Proportion of resistant bacteria for the clinically-relevant antibiotics

    Proportion of resistant bacteria for the clinically-relevant antibiotics (AST data)

    Time frame: Day 7

07

Study locations

1 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Sep 2028, 24 months after the start.

Of 136 non-industry interventional studies with no phase under Urinary Tract Infections, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 39. This study's planned 24 months is close to that.

Counting every sponsor, half of 154 studies reached it within 22 months; a quarter within 8 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2026
First posted
Jun 30, 2026
StartActual
Sep 20, 2026
Primary completionEst.
Sep 26, 2028
CompletionEst.
Sep 26, 2028
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 30, 2026
Sites
7 sites changed recruiting status (6 now not yet recruiting, 1 now recruiting)
Show 7 sites
  • CHRU Tours, Hôpital Trousseau · Chambray-lès-Tours, Franceno status→Not yet recruiting
  • Grenoble university hospital · La Tronche, Franceno status→Not yet recruiting
  • Limoges university hospital · Limoges, Franceno status→Recruiting
  • Hopital lariboisière · Paris, Franceno status→Not yet recruiting
  • Hôpital Saint Louis - APHP · Paris, Franceno status→Not yet recruiting
  • Groupe Hospitalier Universitaire Bichat-Claude Bernard - APHP · Paris, Franceno status→Not yet recruiting
  • CHU de Reims · Reims, Franceno status→Not yet recruiting
Oct 30, 2026
Start date
Sep 15, 2026→Sep 20, 2026 (actual)
Oct 30, 2026
Primary completion
Sep 21, 2028→Sep 26, 2028
Oct 30, 2026
Study completion
Sep 21, 2028→Sep 26, 2028
Oct 30, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • Grenoble university hospital · La Tronche, FranceContact added d•••@chu-grenoble.fr · •••5934Contact added (no phone or email listed)
  • Limoges university hospital · Limoges, FranceContact added t•••@chu-limoges.fr · •••6254Contact added (no phone or email listed)
  • Hopital lariboisière · Paris, FranceContact added a•••@aphp.frContact added (no phone or email listed)
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Not yet recruiting→Recruiting
    7 sites changed recruiting status (6 now not yet recruiting, 1 now recruiting)
    Show 7 sites
    • CHRU Tours, Hôpital Trousseau · Chambray-lès-Tours, Franceno status→Not yet recruiting
    • Grenoble university hospital · La Tronche, Franceno status→Not yet recruiting
    • Limoges university hospital · Limoges, Franceno status→Recruiting
    • Hopital lariboisière · Paris, Franceno status→Not yet recruiting
    • Hôpital Saint Louis - APHP · Paris, Franceno status→Not yet recruiting
    • Groupe Hospitalier Universitaire Bichat-Claude Bernard - APHP · Paris, Franceno status→Not yet recruiting
    • CHU de Reims · Reims, Franceno status→Not yet recruiting
    Start date Sep 15, 2026→Sep 20, 2026 (now actual)
    Primary completion Sep 21, 2028→Sep 26, 2028
    Study completion Sep 21, 2028→Sep 26, 2028
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • Grenoble university hospital · La Tronche, FranceContact added d•••@chu-grenoble.fr · •••5934Contact added (no phone or email listed)
    • Limoges university hospital · Limoges, FranceContact added t•••@chu-limoges.fr · •••6254Contact added (no phone or email listed)
    • Hopital lariboisière · Paris, FranceContact added a•••@aphp.frContact added (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07675018
Responsible party
Sponsor
First posted
Jun 30, 2026
Start date
Sep 20, 2026
Primary completion
Sep 26, 2028 (estimated)
Completion
Sep 26, 2028 (estimated)
Last update
Oct 30, 2026

Study contacts

Olivier BARRAUD, MD
Contact
olivier.barraud@chu-limoges.fr
055505665 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion